Firsekibart

Phase 3Small molecule

RRuijin Hospital

Firsekibart is one of 15 small molecule programs targeting Kawasaki Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kawasaki DiseaseNot yet recruiting

Lupus Erythematosus, SystemicActive, not recruiting

Kawasaki DiseasePreclinical

Not yet recruiting

Lupus Erythematosus, SystemicPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Kawasaki Disease

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Approved

2 2

Coumadin

AAbbott

Approved

1 3

Bayer Aspirin

Bayer

Phase 3

4 4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 5

Ivig

Argenx

Phase 3

6 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 7

Firsekibart

RRuijin Hospital

Phase 3

1 8

Aspirin or Clopidogrel

SSunnybrook Health Sciences Centre

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Active, not recruiting

Still's Disease, Adult-Onset

NCT07191444

Q4 2027

ApprovedActive, not recruiting

Lupus Erythematosus, Systemic

NCT07381465

Q1 2028

PreclinicalNot yet recruiting

Kawasaki Disease

NCT07686770

Clinical

Trials by Indication[1]

Kawasaki Disease1 trial

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease: An Exploratory Randomized Controlled Study

Not yet recruiting·CChildren's Hospital of Fudan University·Preclinical·NCT07686770·90 enrolled

Still's Disease, Adult-Onset1 trial

Efficacy and Safety of Firsekibart Versus Anakinra in Adult-Onset Still's Disease

Active, not recruiting·RRuijin Hospital··NCT07191444·20 enrolled

Lupus Erythematosus, Systemic1 trial

Efficacy and Safety of IL-1 Inhibitors in the Treatment of Mild to Moderate Systemic Lupus Erythematosus With Inadequate Response to Conventional Therapy: A Single-Centre, Single-Arm, Pilot Study

Active, not recruiting·CChinese SLE Treatment And Research Group·Approved·NCT07381465·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Firsekibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Firsekibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Firsekibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRuijin Hospital

Firsekibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Kawasaki Disease1 trial

Still&#39;s Disease, Adult-Onset1 trial

Lupus Erythematosus, Systemic1 trial

References

Drug Info

Quick Facts

Related News

Still's Disease, Adult-Onset1 trial